Elacestrant Impresses in EMERALD Trial of Breast Cancer

Novel Selective Estrogen Receptor Degraders in Advanced Breast Cancer Use of Elacestrant in the Phase III EMERALD Trial - The ASCO Post

Pipeline Report 2022: Patient experience takes center stage

EMERALD: Phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER+ advanced breast cancer

Pharmaceutical Business Review on LinkedIn: #orserdu #breastcancer #menarini #stemline #innovation #oncology…

Elacestrant on course to gain FDA approval

The EMERALD Trial: Elacestrant Mechanism of Action, Study Design, and Outcomes

EMERALD Subgroup Analysis in HER2-Low Metastatic Breast Cancer: Safety and Efficacy of Elacestrant

Forefront Breaking News

ASCO Breast Cancer Session 2021: Panel Discussion